Contineum Therapeutics, Inc. (CTNM) vs Sight Sciences, Inc. (SGHT)
A side-by-side comparison of Contineum Therapeutics, Inc. and Sight Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTNM
Contineum Therapeutics, Inc.
$12.58HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
SGHT
Sight Sciences, Inc.
$8.56HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — CTNM vs SGHT
growth of $100 · dividends reinvested · last 2yCTNM -17.4% (-9.1%/yr)SGHT +59.9% (+26.4%/yr)SGHT compounded faster over this window
CTNM SGHT
CTNM vs SGHT: by the numbers
- •CTNM is the larger company ($473M vs $466M market cap).
- •Both run net losses; CTNM's is the smaller (0.00% vs -35.69% net margin).
Metrics side by side
Valuation
| Metric | CTNM | SGHT |
|---|---|---|
| P/S ratio | N/A | 5.59 |
| P/B ratio | 1.97 | 8.81 |
Profitability
| Metric | CTNM | SGHT |
|---|---|---|
| Gross margin | 0.00% | 87.96% |
| Operating margin | 0.00% | -47.95% |
| Net margin | 0.00% | -35.69% |
| ROE | -24.02% | -56.26% |
| ROIC | -27.22% | -29.50% |
Growth (annualized)
| Metric | CTNM | SGHT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.53% |
| Total return CAGR (5Y) | N/A | -18.69% |
Go deeper
Dig into the metrics
Contineum Therapeutics ROESight Sciences ROEContineum Therapeutics operating marginSight Sciences operating marginContineum Therapeutics revenue growthSight Sciences revenue growthContineum Therapeutics free cash flowSight Sciences free cash flow
Contineum Therapeutics & Sight Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.